For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
Feature|Articles|October 14, 2026
On-Body Injectors: What Oncology Nurses and PAs Need to Know
Author(s)Alex Biese
Fact checked by: By ONN Staff
FDA-approved subcutaneous isatuximab via on-body injector changes myeloma care workflows. Experts outline what nurses and PAs need to know.
Advertisement
Advertisement
The U.S. Food and Drug Administration (FDA) approval of subcutaneous isatuximab-irfc (Sarclisa Escena) for administration by an on-body delivery system gives oncology nurses and physician assistants (PAs) a new way to deliver a cornerstone multiple myeloma therapy. It also offers a preview of a potential broader shift in oncology toward wearable devices that deliver treatment or monitor patients outside the infusion chair.
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Advertisement
Advertisement